ERS Genomics launches ‘Express License’ platform to democratise access to CRISPR/Cas9

Contributed by: GlobeNewswire

Tags

Biotechnology

More Like This

PR Newswire associated0

ToolGen Files Patent Infringement Lawsuit Against Vertex in the United Kingdom

Vertex and CRISPR Therapeutics Announce Authorization of the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), by the United Kingdom MHRA for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

PR Newswire associated0

Solvias to Perform Release Testing on World's First CRISPR-based Gene-Editing Therapy

BIOMAY LAUNCHES FDA-GRADE CRISPR/CAS9 NUCLEASE FOR OFF-THE-SHELF PURCHASE

Jumpcode Genomics and Takara Bio USA Announce Global Patent Partnership

PR Newswire associated0

Okomera Gets €1.5 Million Grant to Develop Microfluidics & AI Powered CRISPR Editing Platform for Target Validation

PR Newswire associated0

Chromatin Bioscience Signs Collaboration Agreement with Astellas

Parse Biosciences Launches Certified Service Provider Program